スポンサーリンク
Kyoto Univ. Hospital Kyoto Jpn | 論文
- TRANSPORT MECHANISMS OF BESTATIN IN INTESTINAL AND RENAL BRUSH-BORDER MEMBRANES
- TRANSPORT MECHANISMS OF β-LACTAM ANTIBIOTICS IN INTESTINAL BRUSH-BORDER MEMBRANES
- TRANSPORT MECHANISMS OF CATIONIC DRUGS IN RAT RENAL BRUSH-BORDER AND BASOLATERAL MEMBRANES
- TRANSPORT OF DRUGS BY PLASMA MEMBRANE VESICLES ISOLATED FROM RAT KIDNEY CORTEX
- Analysis of regulatory polymorphisms in organic ion transporter genes (SLC22A) in the kidney
- Distinct Effects of Omeprazole and Rabeprazole on the Tacrolimus Blood Concentration in a Kidney Transplant Recipient
- Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers
- Evaluation of Calvert's Formula for Dosage Adjustment of Carboplatin in Japanese Patients with Hormone Refractory Prostate Cancer(Biopharmacy)
- わが国における幹細胞を用いた再生医療の指針について
- 早期新生児期のDICパラメータの出生体重・日齢に伴う変化についての検討
- Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer
- ラットにおけるペプチドトランスポータを介するβ-ラクタム抗生物質セフチブテンの吸収に及ぼす亜鉛の阻害効果
- Temporal Decline in Sirolimus Elimination Immediately After Pancreatic Islet Transplantation
- Delayed Effect of Grapefruit Juice on Pharmacokinetics and Pharmacodynamics of Tacrolimus in a Living-Donor Liver Transplant Recipient
- 腎上皮細胞におけるクレアチニンの経細胞輸送
- Required Transient Dose Escalation of Tacrolimus in Living-Donor Liver Transplant Recipients with High Concentrations of a Minor Metabolite M-II in Bile
- Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5
- OE-187 Granulocyte colony-stimulating factor protects cardiac myocytes from mitochondrial injury(Growth factor/Cytokine(01)(H),Oral Presentation(English),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)
- Characterization of chronic idiopathic thrombocytopenic purpura in Japanese children : a retrospective multi-center study
- Significance of chronic marked hyperglycemia on FDG-PET : is it really problematic for clinical oncologic imaging?